[Zurück zum
Forschungsbericht]

MRDAC: CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma (in collaboration with MediGene AG, Martinsried)

Projektbeschreibung:
CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma.

Ansprechpartner: Dr. Ulrike Fasol
Tel: 0049-761-270-7411
Email: ulrike.fasol@uniklinik-freiburg.de
Projektlaufzeit:
Projektbeginn: 01.11.2007
Projektende: 31.10.2008
Projektleitung:
Hennig J.
Stellvertretung: Dr. Martin Büchert
Albert-Ludwigs-Universität Freiburg

Finanzierung:

  • Drittmittel, Firma

Schlagworte:

    MediGene Studie, MRDAC

Aktueller Forschungsbericht